Save up -80% on Brentuximab vedotin
|Note: this is a drug discount program, not an insurance plan.|
|RX BIN: 015558||RX PCN: HT||Group ID: DDN6600||Card Holder ID: DDN6600|
|Pharmacists and Patients support.|
2019 Price of Adcetris
|price without discount in nearest pharmacy. Price may vary.|
We offer free Brentuximab vedotin coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your discount card in most local pharmacies to get a discount on Brentuximab vedotin every time. What are you waiting for? Claim your prescription drug card now!
Get your Prescription
It’s safe and free
Buy drugs in pharmacy
Save money each time
Brentuximab vedotin volume of distribution
The steady state volume of distribution is 6-10 L.
Discount Cards 16,000+
Clients Benefit 29%
Total savings $4,735,080
What is Brentuximab vedotin
Brentuximag vedotin or Adcetris is an antibody-drug conjugate that combines an anti-CD30 antibody and the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Brentuximag vedotin was approved in 2011, and in January 2012, the drug label was revised to include a boxed warning of progressive multifocal leukoencephalopathy and death following JC virus infection.
Brentuximab vedotin mechanism of action
Brentuximab vedotin is composed of 3 parts: a chimeric human-murine IgG1 that targets CD30, monomethyl auristatin E (MMAE),which is a microtubule disrupting agent, and a protease-susceptible linker that covalently links the antibody and MMAE. The IgG1 antibody enables brentuximab vedotin to target tumor cells expressing CD30 on their cell surface then brentuximab vedotin gets internalized into the cell. Once inside, the linker is cleaved releasing MMAE which binds disrupts the microtuble network.
Dosage forms of Brentuximab vedotin
|Injection, powder, lyophilized, for solution||intravenous||50 mg/10.5mL|
|Powder for concentrate for solution for infusion||Intravenous use||50 mg|
|Powder for solution||intravenous||50 mg|
Seattle Genetics, Inc.
Humans and other mammals
Indication of Brentuximab vedotin
Used in the treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma.
Toxicity of Brentuximab vedotin
The most severe toxic reaction seen in patients is progressive multifocal leukoencephalopathy. Other toxicities include bone marrow suppression, infusion reactions, peripheral neuropathy, Stevens-Johnson syndrome, and tumor lysis syndrome.
RX24 Drugs Disclaimer: before buying a Brentuximab vedotin on prescription, consult your healthcare provider. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.